Analysts tap Amgen, Celgene as potential 2012 dealmakers

Analysts are saying the world's biggest biotechs, including Amgen ($AMGN) and Celgene ($CELG), are likely to scout for big acquisitions this year as they seek to revive growth and refill pipelines, Bloomberg reports. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.